Inhibition of intestinal cholesterol absorption decreases atherosclerosis but not adipose tissue inflammation

Journal of Lipid Research

Volumn 53, Issue 11, 2012, Pages 2380-2389

  Umemoto, Tomio ^a,b   Subramanian, Savitha ^a,b   Ding, Yilei ^a,b   Goodspeed, Leela ^a,b   Wang, Shari ^a,b   Han, Chang Yeop ^a,b   Teresa, Antonio Sta ^a   Kim, Jinkyu ^a   O'Brien, Kevin D ^a   Chait, Alan ^a,b  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Ezetimibe; Hepatic steatosis; Insulin resistance; Macrophage

Indexed keywords

CHOLESTEROL; EZETIMIBE; LIPOPROTEIN; SERUM AMYLOID A; SERUM AMYLOID P;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATHEROSCLEROSIS; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG EFFECT; DRUG MECHANISM; GENE EXPRESSION; GLUCOSE HOMEOSTASIS; INFLAMMATION; INSULIN RESISTANCE; INTESTINE ABSORPTION; INTRAABDOMINAL FAT; LIPID ABSORPTION; LIPID ANALYSIS; LIPID BLOOD LEVEL; MALE; MOLECULAR DYNAMICS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN LOCALIZATION; WEIGHT GAIN;

ADIPOSE TISSUE; ANIMALS; ATHEROSCLEROSIS; AZETIDINES; CHOLESTEROL; IMMUNOHISTOCHEMISTRY; INFLAMMATION; INSULIN RESISTANCE; INTESTINAL ABSORPTION; INTESTINES; MACROPHAGES; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTORS, LDL; WEIGHT GAIN;

EID: 84867346639     PISSN: 00222275     EISSN: 15397262     Source Type: Journal    
DOI: 10.1194/jlr.M029264     Document Type: Article

References (46)

1. Després, J-P., S. Moorjani, P. J. Lupien, A. Tremblay, A. Nadeau, and C. Bouchard. 1990. Regional distribution of body fat, plasma lipoproteins, and cardiovascular disease. Arteriosclerosis. 10: 497-511.
2. Weisberg, S. P., D. McCann, M. Desai, M. Rosenbaum, R. L. Leibel, and A. W. Ferrante, Jr. 2003. Obesity is associated with macrophage accumulation in adipose tissue. J. Clin. Invest. 112: 1796-1808. (Pubitemid 38063703)
3. Leinonen, E., E. Hurt-Camejo, O. Wiklund, L. M. Hulten, A. Hiukka, and M. R. Taskinen. 2003. Insulin resistance and adiposity correlate with acute-phase reaction and soluble cell adhesion molecules in type 2 diabetes. Atherosclerosis. 166: 387-394. (Pubitemid 36071698)
4. Yoon, J., S. Subramanian, Y. Ding, S. Wang, L. Goodspeed, B. Sullivan, J. Kim, K. D. O'Brien, and A. Chait. 2011. Chronic insulin therapy reduces adipose tissue macrophage content in LDL-receptor-deficient mice. Diabetologia. 54: 1252-1260.
5. Schenk, S., M. Saberi, and J. M. Olefsky. 2008. Insulin sensitivity: modulation by nutrients and inflammation. J. Clin. Invest. 118: 2992-3002.
6. Subramanian, S., C. Y. Han, T. Chiba, T. S. McMillen, S. A. Wang, A. Haw 3rd, E. A. Kirk, K. D. O'Brien, and A. Chait. 2008. Dietary cholesterol worsens adipose tissue macrophage accumulation and atherosclerosis in obese LDL receptor-deficient mice. Arterioscler. Thromb. Vasc. Biol. 28: 685-691. (Pubitemid 351651333)
7. Shekelle, R. B., A. M. Shryock, O. Paul, M. Lepper, J. Stamler, S. Liu, and W. J. Raynor, Jr. 1981. Diet, serum cholesterol, and death from coronary heart disease. The Western Electric study. N. Engl. J. Med. 304: 65-70. (Pubitemid 11170309)
8. Shekelle, R. B., and J. Stamler. 1989. Dietary cholesterol and ischaemic heart disease. Lancet. 1: 1177-1179.
9. Davidson, M. H. 2003. Ezetimibe: a novel option for lowering cholesterol. Expert Rev. Cardiovasc. Ther. 1: 11-21.
10. Davis, H. R., and E. P. Veltri. 2007. Zetia: inhibition of Niemann-Pick C1 Like 1 (NPC1L1) to reduce intestinal cholesterol absorption and treat hyperlipidemia. J. Atheroscler. Thromb. 14: 99-108.
11. Davis, H. R., Jr., D. S. Compton, L. Hoos, and G. Tetzloff. 2001. Ezetimibe, a potent cholesterol absorption inhibitor, inhibits the development of atherosclerosis in ApoE knockout mice. Arterioscler. Thromb. Vasc. Biol. 21: 2032-2038. (Pubitemid 34219758)
12. Lewis, K. E., E. A. Kirk, T. O. McDonald, S. Wang, T. N. Wight, K. D. O'Brien, and A. Chait. 2004. Increase in serum amyloid a evoked by dietary cholesterol is associated with increased atherosclerosis in mice. Circulation. 110: 540-545. (Pubitemid 39031170)
13. Folch, J., M. Lees, and G. H. Sloane-Stanley. 1957. A simple method for the isolation and purification of total lipids from animal tissues. J. Biol. Chem. 226: 497-509.
14. Subramanian, S., L. Goodspeed, S. Wang, J. Kim, L. Zeng, G. N. Ioannou, W. G. Haigh, M. M. Yeh, K. V. Kowdley, K. D. O'Brien, et al. 2011. Dietary cholesterol exacerbates hepatic steatosis and inflammation in obese LDL receptor-deficient mice. J. Lipid Res. 52: 1626-1635.
15. Uhlar, C. M., and A. S. Whitehead. 1999. Serum amyloid A, the major vertebrate acute-phase reactant. Eur. J. Biochem. 265: 501-523. (Pubitemid 29488982)
16. Han, C. Y., S. Subramanian, C. K. Chan, M. Omer, T. Chiba, T. N. Wight, and A. Chait. 2007. Adipocyte-derived serum amyloid A3 and hyaluronan play a role in monocyte recruitment and adhesion. Diabetes. 56: 2260-2273. (Pubitemid 47358233)
17. Xu, H., G. T. Barnes, Q. Yang, G. Tan, D. Yang, C. J. Chou, J. Sole, A. Nichols, J. S. Ross, L. A. Tartaglia, et al. 2003. Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J. Clin. Invest. 112: 1821-1830. (Pubitemid 38063705)
18. Hotamisligil, G. S., P. Arner, J. F. Caro, R. L. Atkinson, and B. M. Spiegelman. 1995. Increased adipose tissue expression of tumor necrosis factor-alpha in human obesity and insulin resistance. J. Clin. Invest. 95: 2409-2415.
19. Hotamisligil, G. S., N. S. Shargill, and B. M. Spiegelman. 1993. Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science. 259: 87-91. (Pubitemid 23036092)
20. Berg, A. H., and P. E. Scherer. 2005. Adipose tissue, inflammation, and cardiovascular disease. Circ. Res. 96: 939-949. (Pubitemid 40712793)
21. Lionetti, L., M. P. Mollica, A. Lombardi, G. Cavaliere, G. Gifuni, and A. Barletta. 2009. From chronic overnutrition to insulin resistance: the role of fat-storing capacity and inflammation. Nutr. Metab. Cardiovasc. Dis. 19: 146-152.
22. Cersosimo, E., and R. A. DeFronzo. 2006. Insulin resistance and endothelial dysfunction: the road map to cardiovascular diseases. Diabetes Metab. Res. Rev. 22: 423-436. (Pubitemid 44774046)
23. Sowers, J. R., and E. D. Frohlich. 2004. Insulin and insulin resistance: impact on blood pressure and cardiovascular disease. Med. Clin. North Am. 88: 63-82. (Pubitemid 38165387)
24. Hotamisligil, G. S., D. L. Murray, L. N. Choy, and B. M. Spiegelman. 1994. Tumor necrosis factor alpha inhibits signaling from the insulin receptor. Proc. Natl. Acad. Sci. USA. 91: 4854-4858. (Pubitemid 24177748)
25. Ding, Y., S. Subramanian, V. N. Montes, L. Goodspeed, S. Wang, C. Han, A. S. Teresa, 3rd, J. Kim, K. D. O'Brien, and A. Chait. 2012. Toll-like receptor 4 deficiency decreases atherosclerosis but does not protect against inflammation in obese low-density lipoprotein receptor-deficient mice. Arterioscler. Thromb. Vasc. Biol. 32: 1596-1604.
26. Labonté, E. D., L. M. Camarota, J. C. Rojas, R. J. Jandacek, D. E. Gilham, J. P. Davies, Y. A. Ioannou, P. Tso, D. Y. Hui, and P. N. Howles. 2008. Reduced absorption of saturated fatty acids and resistance to diet-induced obesity and diabetes by ezetimibe-treated and Npc1l1-/- mice. Am. J. Physiol. Gastrointest. Liver Physiol. 295: G776-G783.
27. Muraoka, T., K. Aoki, T. Iwasaki, K. Shinoda, A. Nakamura, H. Aburatani, S. Mori, K. Tokuyama, N. Kubota, T. Kadowaki, et al. 2011. Ezetimibe decreases SREBP-1c expression in liver and reverses hepatic insulin resistance in mice fed a high-fat diet. Metabolism. 60: 617-628.
28. Paraskevas, K. I., A. Pantopoulou, I. S. Vlachos, G. Agrogiannis, D. G. Iliopoulos, G. Karatzas, D. Tzivras, D. P. Mikhailidis, and D. N. Perrea. 2011. Comparison of fibrate, ezetimibe, low- and high-dose statin therapy for the dyslipidemia of the metabolic syndrome in a mouse model. Angiology. 62: 144-154.
29. Nakagami, H., M. K. Osako, Y. Takami, R. Hanayama, H. Koriyama, M. Mori, H. Hayashi, H. Shimizu, and R. Morishita. 2009. Vascular protective effects of ezetimibe in ApoE-deficient mice. Atherosclerosis. 203: 51-58.
30. Ridker, P. M., J. E. Buring, N. R. Cook, and N. Rifai. 2003. C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14 719 initially healthy American women. Circulation. 107: 391-397.
31. Kotani, K., N. Asahara-Satoh, Y. Kato, R. Araki, A. Himeno, H. Yamakage, K. Koyama, M. Tanabe, M. Oishi, T. Okajima, et al. 2011. Remnant-like particle cholesterol and serum amyloid A-low-density lipoprotein levels in obese subjects with metabolic syndrome. J. Clin. Lipidol. 5: 395-400.
32. Kotronen, A., and H. Yki-Jarvinen. 2008. Fatty liver: a novel component of the metabolic syndrome. Arterioscler. Thromb. Vasc. Biol. 28: 27-38.
33. Browning, J. D., and J. D. Horton. 2004. Molecular mediators of hepatic steatosis and liver injury. J. Clin. Invest. 114: 147-152. (Pubitemid 39071617)
34. Shiri-Sverdlov, R., K. Wouters, P. J. van Gorp, M. J. Gijbels, B. Noel, L. Buffat, B. Staels, N. Maeda, M. van Bilsen, and M. H. Hofker. 2006. Early diet-induced non-alcoholic steatohepatitis in APOE2 knock-in mice and its prevention by fibrates. J. Hepatol. 44: 732-741.
35. Schattenberg, J. M., and P. R. Galle. 2010. Animal models of non-alcoholic steatohepatitis: of mice and man. Dig. Dis. 28: 247-254.
36. Zheng, S., L. Hoos, J. Cook, G. Tetzloff, H. Davis, Jr., M. van Heek, and J. J. Hwa. 2008. Ezetimibe improves high fat and cholesterol diet-induced non-alcoholic fatty liver disease in mice. Eur. J. Pharmacol. 584: 118-124.
37. Fukuda, M., T. Nakamura, K. Kataoka, H. Nako, Y. Tokutomi, Y. F. Dong, O. Yasuda, H. Ogawa, and S. Kim-Mitsuyama. 2010. Ezetimibe ameliorates cardiovascular complications and hepatic steatosis in obese and type 2 diabetic db/db mice. J. Pharmacol. Exp. Ther. 335: 70-75.
38. Nozaki, Y., K. Fujita, M. Yoneda, K. Wada, Y. Shinohara, H. Takahashi, H. Kirikoshi, M. Inamori, K. Kubota, S. Saito, et al. 2009. Long-term combination therapy of ezetimibe and acarbose for non-alcoholic fatty liver disease. J. Hepatol. 51: 548-556.
39. Jia, L., Y. Ma, S. Rong, J. L. Betters, P. Xie, S. Chung, N. Wang, W. Tang, and L. Yu. 2010. Niemann-Pick C1-Like 1 deletion in mice prevents high-fat diet-induced fatty liver by reducing lipogenesis. J. Lipid Res. 51: 3135-3144.
40. Tremblay, A. J., B. Lamarche, J. C. Hogue, and P. Couture. 2009. Effects of ezetimibe and simvastatin on apolipoprotein B metabolism in males with mixed hyperlipidemia. J. Lipid Res. 50: 1463-1471.
41. Tremblay, A. J., B. Lamarche, J. S. Cohn, J. C. Hogue, and P. Couture. 2006. Effect of ezetimibe on the in vivo kinetics of apoB-48 and apoB-100 in men with primary hypercholesterolemia. Arterioscler. Thromb. Vasc. Biol. 26: 1101-1106. (Pubitemid 43732118)
42. Yunoki, K., K. Nakamura, T. Miyoshi, K. Enko, K. Kohno, H. Morita, K. F. Kusano, and H. Ito. 2011. Ezetimibe improves postprandial hyperlipemia and its induced endothelial dysfunction. Atherosclerosis. 217: 486-491.
43. Bozzetto, L., G. Annuzzi, G. D. Corte, L. Patti, P. Cipriano, A. Mangione, G. Riccardi, and A. A. Rivellese. 2011. Ezetimibe beneficially influences fasting and postprandial triglyceride-rich lipoproteins in type 2 diabetes. Atherosclerosis. 217: 142-148.
44. Chan, D. C., G. F. Watts, S. K. Gan, E. M. Ooi, and P. H. Barrett. 2010. Effect of ezetimibe on hepatic fat, inflammatory markers, and apolipoprotein B-100 kinetics in insulin-resistant obese subjects on a weight loss diet. Diabetes Care. 33: 1134-1139.
45. Cannon, C. P., R. P. Giugliano, M. A. Blazing, R. A. Harrington, J. L. Peterson, C. M. Sisk, J. Strony, T. A. Musliner, C. H. McCabe, E. Veltri, et al. 2008. Rationale and design of IMPROVE-IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial): comparison of ezetimbe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes in patients with acute coronary syndromes. Am. Heart J. 156: 826-832.
46. Park, H., T. Shima, K. Yamaguchi, H. Mitsuyoshi, M. Minami, K. Yasui, Y. Itoh, T. Yoshikawa, M. Fukui, G. Hasegawa, et al. 2011. Efficacy of long-term ezetimibe therapy in patients with nonalcoholic fatty liver disease. J. Gastroenterol. 46: 101-107.